06
Oct

Buyout-hungry Actavis–which is alternatively spotlighted as both a buyer and a possible buyout target–has snapped up Chicago-based Durata Therapeutics and its recently approved antibiotic Dalvance (dalbavancin) for $675 million plus a potential bonus.

…read more

Source: Actavis snaps up Durata, newly approved antibiotic in $675M buyout

    

0 No comments